The role of preoperative systemic treatment in patients with breast cancer

The goal of preoperative pharmacotherapy in patients with breast cancer is to enable breast conserving surgery in stage T3N0-1M0 or radical mastectomy in patients with primary inoperative tumors (T1-4N0-3M0). The choice of optimal treatment should be based not only on risk factors resulting from th...

Full description

Bibliographic Details
Main Authors: Sylwia Dębska-Szmich, Magdalena Krakowska, Urszula Czernek, Maja Habib-Lisik, Agnieszka Zięba, Piotr Potemski
Format: Article
Language:English
Published: Termedia Publishing House 2016-06-01
Series:Contemporary Oncology
Subjects:
Online Access:https://www.termedia.pl/The-role-of-preoperative-systemic-treatment-in-patients-with-breast-cancer,3,27626,1,1.html
id doaj-8fcdfa0394ee4f00822943dfd43c8f15
record_format Article
spelling doaj-8fcdfa0394ee4f00822943dfd43c8f152020-11-25T00:34:42ZengTermedia Publishing HouseContemporary Oncology1428-25261897-43092016-06-012029310110.5114/wo.2016.6006727626The role of preoperative systemic treatment in patients with breast cancerSylwia Dębska-SzmichMagdalena KrakowskaUrszula CzernekMaja Habib-LisikAgnieszka ZiębaPiotr PotemskiThe goal of preoperative pharmacotherapy in patients with breast cancer is to enable breast conserving surgery in stage T3N0-1M0 or radical mastectomy in patients with primary inoperative tumors (T1-4N0-3M0). The choice of optimal treatment should be based not only on risk factors resulting from the stage but also on predicted cancer responsiveness to the treatment. The breast cancer subtypes defined by immunohistochemical profile (expression of ER, PR, HER2 and Ki67) are characterized by different responsiveness to therapy. Complete response confirmed by histopathological evaluation after neoadjuvant chemotherapy is a positive prognostic factor in some breast cancer subtypes. This marker is not of value in postmenopausal patients with ER/PR+ HER2– tumors, who are candidates for neoadjuvant hormone therapy. These patients have a good prognosis if in a histopathological report after surgery there are features such as pT1, pN0, Ki67 < 3%, and ER Allred score ≥ 3. The goal of the paper is to present current knowledge about preoperative pharmacotherapy of breast cancer.https://www.termedia.pl/The-role-of-preoperative-systemic-treatment-in-patients-with-breast-cancer,3,27626,1,1.htmlpreoperative systemic treatment complete pathological response breast cancer subtypes
collection DOAJ
language English
format Article
sources DOAJ
author Sylwia Dębska-Szmich
Magdalena Krakowska
Urszula Czernek
Maja Habib-Lisik
Agnieszka Zięba
Piotr Potemski
spellingShingle Sylwia Dębska-Szmich
Magdalena Krakowska
Urszula Czernek
Maja Habib-Lisik
Agnieszka Zięba
Piotr Potemski
The role of preoperative systemic treatment in patients with breast cancer
Contemporary Oncology
preoperative systemic treatment
complete pathological response
breast cancer subtypes
author_facet Sylwia Dębska-Szmich
Magdalena Krakowska
Urszula Czernek
Maja Habib-Lisik
Agnieszka Zięba
Piotr Potemski
author_sort Sylwia Dębska-Szmich
title The role of preoperative systemic treatment in patients with breast cancer
title_short The role of preoperative systemic treatment in patients with breast cancer
title_full The role of preoperative systemic treatment in patients with breast cancer
title_fullStr The role of preoperative systemic treatment in patients with breast cancer
title_full_unstemmed The role of preoperative systemic treatment in patients with breast cancer
title_sort role of preoperative systemic treatment in patients with breast cancer
publisher Termedia Publishing House
series Contemporary Oncology
issn 1428-2526
1897-4309
publishDate 2016-06-01
description The goal of preoperative pharmacotherapy in patients with breast cancer is to enable breast conserving surgery in stage T3N0-1M0 or radical mastectomy in patients with primary inoperative tumors (T1-4N0-3M0). The choice of optimal treatment should be based not only on risk factors resulting from the stage but also on predicted cancer responsiveness to the treatment. The breast cancer subtypes defined by immunohistochemical profile (expression of ER, PR, HER2 and Ki67) are characterized by different responsiveness to therapy. Complete response confirmed by histopathological evaluation after neoadjuvant chemotherapy is a positive prognostic factor in some breast cancer subtypes. This marker is not of value in postmenopausal patients with ER/PR+ HER2– tumors, who are candidates for neoadjuvant hormone therapy. These patients have a good prognosis if in a histopathological report after surgery there are features such as pT1, pN0, Ki67 < 3%, and ER Allred score ≥ 3. The goal of the paper is to present current knowledge about preoperative pharmacotherapy of breast cancer.
topic preoperative systemic treatment
complete pathological response
breast cancer subtypes
url https://www.termedia.pl/The-role-of-preoperative-systemic-treatment-in-patients-with-breast-cancer,3,27626,1,1.html
work_keys_str_mv AT sylwiadebskaszmich theroleofpreoperativesystemictreatmentinpatientswithbreastcancer
AT magdalenakrakowska theroleofpreoperativesystemictreatmentinpatientswithbreastcancer
AT urszulaczernek theroleofpreoperativesystemictreatmentinpatientswithbreastcancer
AT majahabiblisik theroleofpreoperativesystemictreatmentinpatientswithbreastcancer
AT agnieszkazieba theroleofpreoperativesystemictreatmentinpatientswithbreastcancer
AT piotrpotemski theroleofpreoperativesystemictreatmentinpatientswithbreastcancer
AT sylwiadebskaszmich roleofpreoperativesystemictreatmentinpatientswithbreastcancer
AT magdalenakrakowska roleofpreoperativesystemictreatmentinpatientswithbreastcancer
AT urszulaczernek roleofpreoperativesystemictreatmentinpatientswithbreastcancer
AT majahabiblisik roleofpreoperativesystemictreatmentinpatientswithbreastcancer
AT agnieszkazieba roleofpreoperativesystemictreatmentinpatientswithbreastcancer
AT piotrpotemski roleofpreoperativesystemictreatmentinpatientswithbreastcancer
_version_ 1725311949615398912